IPF, a vesicular uptake inhibitory protein factor, can reduce the Ca 2+ -dependent, evoked release of glutamate, GABA and serotonin by Tamura, Yutaka et al.
q 2001 International Society for Neurochemistry, Journal of Neurochemistry, 76, 1153±1164 1153
Journal of Neurochemistry, 2001, 76, 1153±1164
IPF, a vesicular uptake inhibitory protein factor, can reduce the
Ca21-dependent, evoked release of glutamate, GABA and
serotonin
Yutaka Tamura,*,1 Eric D. OÈ zkan,*,2 David G. Bole* and Tetsufumi Ueda*,²,³
*Mental Health Research Institute and Departments of ²Pharmacology and ³Psychiatry, Medical School,
The University of Michigan, Ann Arbor, Michigan, USA
Abstract
Synaptic vesicles in the nerve terminal play a pivotal role in
neurotransmission. Neurotransmitter accumulation into
synaptic vesicles is catalyzed by distinct vesicular trans-
porters, harnessing an electrochemical proton gradient
generated by V-type proton-pump ATPase. However, little is
known about regulation of the transmitter pool size,
particularly in regard to amino acid neurotransmitters. We
previously provided evidence for the existence of a potent
endogenous inhibitory protein factor (IPF), which causes
reduction of glutamate and GABA accumulation into
isolated, puri®ed synaptic vesicles. In this study we demon-
strate that IPF is concentrated most in the synaptosomal
cytosol fraction and that, when introduced into the synapto-
some, it leads to a decrease in calcium-dependent exocytotic
(but not calcium-independent) release of glutamate in a
concentration-dependent manner. In contrast, a-fodrin (non-
erythroid spectrin), which is structurally related to IPF and
thought to serve as the precursor for IPF, is devoid of such
inhibitory activity. Intrasynaptosomal IPF also caused reduc-
tion in exocytotic release of GABA and the monoamine
neurotransmitter serotonin. Whether IPF affects vesicular
storage of multiple neurotransmitters in vivo would depend
upon the localization of IPF. These results raise the
possibility that IPF may modulate synaptic transmission by
acting as a quantal size regulator of one or more neuro-
transmitters.
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regulation, vesicular storage.
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It is now widely accepted that glutamate functions as the
major excitatory neurotransmitter in the vertebrate central
nervous system (Fonnum 1984; Collingridge and Bliss
1987; Cotman et al. 1987; Watkins et al. 1990). As such,
proper glutamate transmission is required for learning and
memory formation (Collingridge and Bliss 1987; Cotman
et al. 1988; Zalutsky and Nicoll 1990; Malgaroli and Tsien
1992; Bliss and Collingridge 1993). Aberrant glutamate
transmission has been implicated in a variety of neurological
and psychiatric disorders, including epilepsy, ischemia-
induced neuronal cell death, Huntington's chorea,
Alzheimer's disease and schizophrenia (Choi and Rothman
1990; Meldrum 1991; Coyle and Puttfarcken 1993; Bradford
1995; Bunney et al. 1995; Chapman 1998; Moghaddam and
Adams 1998). Glutamate transmission is postsynaptically
mediated by various, distinct types of receptors, namely,
AMPA, kainate and NMDA receptor/channels, and metabo-
tropic receptors coupled to phosphatidyl inositol bisphos-
phate lipase C and adenylate cyclase (Sladeczek et al. 1988;
Monaghan et al. 1989; Watkins et al. 1990; Nakanishi 1992;
Hollmann and Heinemann 1994).
Presynaptically, despite the past controversy, evidence
has now accumulated to strongly support the concept that
synaptic vesicles play a pivotal role in glutamate synaptic
transmission (Ueda 1986; Nicholls 1989; Maycox et al.
1990; OÈ zkan and Ueda 1998). Both highly speci®c,
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ATP-dependent, glutamate accumulation into isolated
synaptic vesicles (Naito and Ueda 1983; Naito and Ueda
1985; Maycox et al. 1988; Cidon and Sihra 1989; Fykse
et al. 1989; Tabb et al. 1992; Moriyama and Yamamoto
1995) and enrichment of glutamate in the synaptic vesicles
(Storm-Mathisen et al. 1983; Burger et al. 1989) have been
demonstrated. A variety of evidence indicates that glutamate
is taken up into synaptic vesicles via a mechanism coupled
to the electrochemical proton gradient DmH
1. This gradient
is composed of the membrane potential (Dc) and the
transmembrane pH difference (DpH), generated by a
vacuolar type of proton-pump ATPase in the synaptic
vesicle membrane. Although the membrane potential alone
can drive glutamate uptake (Maycox et al. 1988; Cidon and
Sihra 1989; Tabb et al. 1992), both elements of DmH
1,
namely membrane potential and pH gradient, are important
for maximal uptake activity seen under physiologically
relevant Cl2 concentrations (Naito and Ueda 1985; Tabb
et al. 1992; Wolosker et al. 1996; Bellocchio et al. 2000). It
has recently been demonstrated that BNPI, a brain-speci®c
Na1-dependent inorganic phosphate transporter (Ni et al.
1994) functions as a vesicular glutamate transporter
(Bellocchio et al. 2000; Takamori et al. 2000). However,
it has a rather restricted distribution in the brain and hence is
thought to represent an isoform of the vesicular glutamate
transporter (Bellocchio et al. 2000). Nicholls and associates
(Nicholls and Sihra 1986; McMahon and Nicholls 1991);
Kish and Ueda (1991); Wilson and associates (Mehta et al.
1996) and Takamori et al. (2000) have provided evidence
that glutamate is released from synaptic vesicles by an
exocytotic mechanism.
Vesicular accumulation of glutamate thus plays a crucial
role in directing the common biochemical glutamate toward
the neurotransmitter pathway and diverting it away from the
general metabolic pathway (Ueda 1986; OÈ zkan and Ueda
1998). Since branch points in biochemical pathways are
often sites of regulation, we postulated that vesicular
glutamate uptake may be subject to such regulation. In
light of these considerations, we obtained evidence for the
existence of a potent inhibitory protein (Lobur et al. 1990;
OÈ zkan et al. 1997) that may serve as an endogenous
modulator for this process. This protein, designated as
inhibitory protein factor (IPF), inhibits ATP-dependent
accumulation of not only glutamate but also GABA
(g-aminobutyric acid), whereas it exhibits no inhibition of
Na1-dependent glutamate uptake into synaptosomes (OÈ zkan
et al. 1997). IPF appears to be derived from the a subunit of
the cytoskeletal protein fodrin (non-erythroid or brain
spectrin), by at least two steps of cleavage, generating the
distinct N-terminal sequence YHRFKELSTLRRAKLED-
SYR, although the alternative possibility is not entirely ruled
out that it is synthesized de novo according to the nucleotide
sequence of a speci®c `IPF mRNA'. In contrast to IPF,
neither isolated fodrin nor its a subunit exhibits inhibitory
activity. Although fodrin is known to occur in virtually all
cells, contributing to the cytoskeletal structure (Goodman
et al. 1995), the cellular and subcellular localization of IPF,
as well as its physiological function, remains to be
elucidated. In this communication, we report evidence
suggesting that IPF is associated with synaptic vesicles.
Moreover, in an effort to demonstrate that IPF functions
within the nerve terminal as a potential regulator of
exocytotic release of glutamate (and possibly of other
neurotransmitters as well), we have introduced isolated IPF
into synaptosomes and examined its effect on subsequent,
depolarization-induced Ca21-dependent release of gluta-
mate, GABA and serotonin. We present evidence here that
isolated IPF, when permeated into synaptosomes, leads to a
decrease in exocytotic release of these neurotransmitters.
Part of this work was previously presented in abstract form
(Tamura et al. 1998).
Materials and methods
Puri®cation of IPF and fodrin
IPF was puri®ed by the method of OÈ zkan et al. (1997). Two Mono
Q-puri®ed fractions rich in IPFa and IPFbg, respectively, were
used in the experiments described here. The latter preparation
contained a mixture of IPFb and IPFg. Fodrin and its a subunit
were puri®ed from bovine brain by the procedures described by
Bennett et al. (1986) and Calvert et al. (1980), respectively.
Fig. 1 Effect of DMSO presence, during the freeze/thaw period, on
exocytotic release of glutamate. Synaptosomes were suspended in
solution A (2 mg/mL) containing [3H]glutamate, with or without 5%
DMSO, and frozen for 3 min. Samples were then thawed and pro-
cessed as described in Materials and methods. Glutamate release
was allowed to proceed for 20 and 40 s. The amounts of [3H] gluta-
mate released at 0 s, 20 s (52.7 mM KCl, 1 Ca21), and 40 s
(52.7 mM KCl, 1 Ca21) in the presence of DMSO represented
0.20 1 0.02%, 0.53 1 0.04%, and 0.66 1 0.06%, respectively, of
the total [3H] glutamate added to load synaptosomes. The data
represent the mean ^SEM of 4 independent experiments, using 4
separate synaptosome preparations.
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Preparation of synaptosomes
Crude synaptosomes were prepared at 48C by a modi®cation of
the method of Krueger et al. (1977). Male Sprague-Dawley rats
(190±200 g) were killed by decapitation. The brain was removed
within 1 min after decapitation and hemisected. Cerebellum,
brainstem and white matter were removed from each hemisphere.
One and a half grams of cerebrum were homogenized in 10 mL of
ice-cold 0.32 m sucrose in 4 mm Tris±HCl, pH 7.4 (sucrose
solution), with 12 up-and-down strokes in a glass-Te¯on homo-
genizer. The homogenate was diluted with 5 mL of sucrose
solution and centrifuged at 1000 gmax for 10 min. The supernatant
was removed with a pipette and the pellet rehomogenized in
10 mL of sucrose solution with 4 up-and-down strokes, and
centrifuged at 1000 gmax for 10 min. The supernatants were
combined and centrifuged at 1000 gmax for 10 min, and the
pellet discarded. The supernatant was then centrifuged at
12 500 gmax for 15 min; the pellet was washed by resuspending
in 15 mL of sucrose solution and centrifuging at 12 500 gmax for
15 min. The resulting pellet (P2) was used as the crude
synaptosome preparation in all experiments described here.
Protein was quanti®ed with the Coomassie Protein Assay Kit
from Pierce (Rockford, IL, USA), with bovine serum albumin as
standard.
Introduction of isolated IPF and fodrin into synaptosomes
Freshly prepared synaptosomes were frozen/thawed by a modi®ca-
tion of the method of Nichols et al. (1989). The synaptosome
preparation was resuspended in 200 mL of oxygenated solution A
(140 mm K1-gluconate; 4 mm KCl; 4 mm MgSO4; 2 mm Tris±
ATP; 20 mm HEPES; 50 mm glutamate, pH 7.4) at 3.75 mg/mL,
except for experiments in Figs 1 and 2, in which the synaptosome
protein concentration was 4 times higher. Isolated IPF was added to
the synaptosome suspension. In control experiments, 50 mL of
solution A were added instead of IPF. In vehicle experiments,
50 mL of the medium (300 mm NaCl in 20 mm Tris±HCl buffer,
pH 7.4), in which IPF had been dissolved, were added, instead of
IPF. To each mixture, 117.5 mL of solution A were added, followed
by addition of 7.5 mL of l-[G-3H]glutamate (50 Ci/mmol,
Amersham Pharmacia Biotech, Piscataway, NJ, USA) (7.5 mCi).
The total volume of the mixture was 375 mL, to which 375 mL of
10% dimethylsulfoxide (DMSO) (Fisher Scienti®c, Pittsburgh, PA,
USA) in solution A were added, rendering the ®nal concentration of
DMSO 5%. The entire mixture (750 mL) was frozen for 3 min in
an isopropyl alcohol/dry ice bath. The frozen samples were thawed
at 1±48C with periodic agitation over 10 min. Permeabilization and
resealing of synaptosomes were carried out in the presence of Mg-
ATP and the low concentration of chloride (4 mm) as described
above, allowing selective glutamate uptake into synaptic vesicles
within the synaptosome during the subsequent incubation at 308C
for 10 min. These conditions have been shown to give rise to
maximal uptake of glutamate into isolated synaptic vesicles (Naito
and Ueda 1985; Carlson et al. 1989; Fykse et al. 1989; Tabb et al.
1992; Hartinger and Jahn 1993; Wolosker et al. 1996; Bellocchio
et al. 2000). This procedure permitted us to selectively monitor
exocytotic release with ease. At the end of the thawing period, the
samples were rapidly diluted with 10 mL of oxygenated balanced
salt solution (BSS); 116.4 mm NaCl; 5.4 mm KCl; 1.3 mm MgSO4;
0.92 mm Na2HPO4; 26.2 mm NaHCO3; 11 mm glucose; 0.1 mm
EGTA, pH 7.4) and centrifuged at 10 000 gmax for 10 min. The
pellets were suspended in 1.5 mL of BSS and incubated for 10 min
at 308C. At the end of the incubation period, the extrasynaptosomal
medium was removed by centrifugation at 10 000 gmax for 10 min.
The pelleted synaptosomes were washed twice by resuspending in
10 mL of BSS and centrifuging at 10 000 gmax for 10 min. The
washed synaptosome preparation was resuspended in 1.5 mL of
oxygenated BSS. Isolated fodrin or a-fodrin was introduced into
synaptosomes by the same method described above.
Assay for glutamate release
[3H]Glutamate-loaded, resealed and washed synaptosomes (in
1.5 mL of BSS) were preincubated at 308C for 1.5 min. Aliquots
(150 mL) were mixed with 150 mL of the following preoxygenated
release solutions at 308C (RS 1±4) and incubated at 308C for
various periods of time as follows:
RS 1: 116.4 mm NaCl, 5.4 mm KCl, 1.3 mm MgSO4, 0.92 mm
Na2HPO4, 26.2 mm NaHCO3, 11 mm glucose, 0.1 mm EGTA, and
4 mm dl-threo-b-hydroxy aspartate (pH 7.4)
RS 2: RS 1 plus 2.6 mm CaCl2
RS 3: RS 1 plus 94.6 mm KCl minus 94.6 mm NaCl
RS 4: RS 3 plus 2.6 mm CaCl2
Release was stopped by placing the samples on ice, followed by
centrifugation at 10 000 gmax for 10 min at 48C. Radioactivity in
Fig. 2 Time course of glutamate release from permeabilized and
resealed synaptosomes. Aliquots (150 mL) of [3H]glutamate-loaded,
permeabilized/resealed synaptosomes (2 mg/mL) were mixed with
150 mL each of solution RS 3 or RS 4 (a) and solution RS1 or RS2
(b), as described in Materials and methods, and incubated at 308C
for 0, 10, 20, 40 and 60 s. Samples were processed as described in
Materials and methods. The value at 0-s incubation has been sub-
tracted from all data. The values subtracted were 18 967 d.p.m.
(Ca21 present) and 20 337 d.p.m. (Ca21 absent) for (a), and 16 348
d.p.m. (Ca21 present) and 17 997 d.p.m. (Ca21 absent) for (b),
respectively. The amounts of [3H] glutamate released during 60 s in
the presence and absence of Ca21 represented 0.67 1 0.034% and
0.04 1 0.002% for (a), and 0.05 1 0.02% and 0.03 1 0.015% for
(b), respectively, of the total amount of [3H] glutamate added to load
synaptosomes. The data represent the mean ^SEM of 3 indepen-
dent experiments, using 3 separate synaptosome preparations. (a)
[3H]glutamate release in the presence (X) or absence (W) of Ca21
(1.3 mM) under depolarization conditions (i.e. in the presence of
52.7 mM KCl). (b) [3H]glutamate release in the presence (X) or
absence (W) of Ca21 (1.3 mM) under non-depolarizing conditions
(i.e. in the presence of 5.4 mM KCl). Unpaired Student's t-test
p-values (open circle vs. closed circle): *p  0.02; **p  0.005;
***p , 0.0001.
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the 250-mL aliquot of the supernatant was determined in a
Beckman LS 6500 scintillation spectrophotometer.
Assay for GABA and serotonin release
The assay conditions for GABA and serotonin release were the
same described for the glutamate release assay, except that (a)
[3H]glutamate was replaced by 7.5 mCi of 4-amino-n-[2,3±3H]
butyric acid (50 Ci/mmol) or 5-hydroxy[G-3H]tryptamine, creatine
sulfate (13.8 Ci/mmol) (both from Amersham Pharmacia Biotech),
and (b) 50 mm glutamate was replaced by 50 mm GABA or 50 mm
serotonin.
Monitoring IPF and Fodrin contents in the synaptosome
IPF and fodrin were incorporated into the synaptosome as described
above, except for the omission of [3H]glutamate. The IPF-or fodrin-
containing synaptosomes described above were incubated for
10 min at 308C, followed by centrifuged at 10 000 gmax for
10 min. The pellet was washed twice and resuspended in 1.5 mL of
6 mm Tris±maleate (pH 8.3) for 45 min to lyse synaptosomes, and
centrifuged at 10 000 gmax for 10 min. The resulting supernatant
was concentrated by using a vacuum centrifuge (,5-fold), and
subjected to sodium dodecyl sulfate (SDS)/6% polyacrylamide gel
electrophoresis, followed by electrophoretic transfer onto the
nitrocellulose membrane (BioRad, Hercules, CA, USA); the
transfer buffer contained 20% methanol, 192 nm glycine, and
25 mm Tris±HCl, pH 8.3. Blots were incubated with polyclonal
antibodies raised against the N-terminal decapeptide of IPF
(YHRFKELSTL) or of a-fodrin (MPSGVKVLE) and were
visualized by enhanced chemiluminescence (ECL), according to
the manufacturer's instructions (Amersham Pharmacia Biotech).
Chemiluminescent blots were exposed to Hyper®lm ECL for
10 min at room temperature. The primary polyclonal antibodies to
the N-terminal decapeptides of IPF and a-fodrin were raised in
rabbits (Research Genetics, Huntsville, AL, USA); the former was
shown to selectively recognize IPF and a-fodrin in a freshly
prepared brain homogenate, as well as to interact with puri®ed IPF
and a-fodrin, as judged by Western blots probed with horseradish
peroxidase (Amano et al. in preparation).
Subcellular fractionation
Subcellular fractions of rat brain were obtained by a modi®cation of
the procedure described in detail for canine cerebral cortex (Ueda
et al. 1979). Brie¯y, ®ve forebrains from 150±200 g Sprague-
Dawley rats were homogenized in 10 volumes of 0.32 m sucrose,
1 mm NaHCO3, 1 mm EDTA, 1 mm EGTA, 3 mm benzamidine,
and 0.3 mm phenylmethylsulfonyl ¯uoride (PMSF). Forebrains
were dispersed by 10 strokes with a Dounce homogenizer
(Thomas C270) rotating at 800 r.p.m. Differential centrifugation
produced a nuclear and cell debris pellet (P1) (10 min, 1400 gave), a
crude mitochondrial plus synaptosomal pellet (P2) (10 min,
13 800 gave), a microsomal pellet (P3) (60 min, 105 000 gave),
and the ®nal perikaryon supernatant (S1). The P1 pellet was washed
once with the homogenization buffer. The P2 pellet was suspended
in a minimal volume of homogenization buffer and osmotically
shocked by addition of 9 volumes of ice cold 6 mm Tris±maleate,
pH 8.1, containing 0.3 mm PMSF. After 45 min on ice, the
osmotically shocked P2 fraction was centrifuged (20 min,
32 800 gave) to yield a plasma membrane/mitochondrial/myelin
pellet (P4) and a supernatant containing synaptic vesicles (SV)
and synaptosomal cytosol (S2). Crude synaptic vesicles (SV) and
synaptosomal cytosol (S2) were separated by centrifugation
(60 min, 105 000 gave). The crude synaptic vesicle fraction (SV)
was suspended in 0.32 m homogenization buffer and subjected to
centrifugation (120 min, 64 700 gave) on a discontinuous sucrose
gradient consisting of equal volumes of 0.4 m, 0.6 m, and 0.8 m
sucrose. Following centrifugation, ®ve fractions were recovered
and contained: the top 0.32 m sucrose sample layer and the 0.32 m/
0.4 m sucrose interface (fraction A), 0.4 m sucrose layer and the
0.4 m/0.6 m sucrose interface (fraction B), 0.6 m sucrose layer and
the 0.6/0.8 m sucrose interface (fraction C), 0.8 m sucrose layer
(fraction D), and pelleted material at the bottom of the tube
(fraction E). Each fraction A±D was diluted to 0.25 m sucrose and
centrifuged (60 min, 105 000 gave) to pellet synaptic vesicles and
membrane fragments. Resulting pellets were suspended in a
minimal volume of homogenization buffer (0.32 m sucrose),
assayed for protein content, and stored at 2808C. Fraction B had
previously been shown to be rich in synaptic vesicles (Ueda et al.
1979). The amount of protein in each fraction was determined by
the Bradford method (Pierce Coomassie Protein Assay Reagent)
using bovine serum albumin as protein standard.
Western blotting of subcellular fractions
Proteins in the subcellular fractions obtained above were separated
by SDS polyacrylamide gel (6%) electrophoresis (Laemmli 1970)
and electrophoretically transferred onto the 0.45 m nitrocellulose
membrane (BioRad). The electrophoretic transfer buffer contained
15.6 mm Tris base, 120 mm glycine, and 0.1% SDS, pH 8.3.
Electrophoretic transfer was conducted for 1 h at 100 V (constant
voltage) in a BioRad mini trans-blot electrophoretic transfer cell.
Nitrocellulose blots were blocked with 5% non-fat dried milk
dissolved in TBS (20 mm Tris±HCl, 0.5 m NaCl, pH 8.3).
Nitrocellulose blots were incubated with a primary antibody
followed by an alkaline phosphase-conjugated goat antirabbit IgG
antibody (Sigma). Unbound antiserum or alkaline phosphatase-
conjugated secondary antibody was removed by 3 sequential
washes with TBS containing 0.1% Tween 20. IPF antisera were
raised in rabbits by immunization with the synthetic decapeptide
corresponding to the N-terminal sequence of IPF (OÈ zkan et al.
1997). BCIP and NBT were utilized as the substrate mixture for
detection of bound alkaline phosphatase-conjugated secondary
antibody (BioRad).
Results
Synaptosomes retain exocytotic ability after brief freeze
treatment in DMSO
Synaptosomes, which had been frozen for 3 min in the
presence of the cryoprotectant DMSO, followed by thawing
at 1±48C, were tested for the ability to exocytose the
neurotransmitter glutamate. Fig. 1 shows K1-evoked [3H]
glutamate release from synaptosomes frozen and thawed in
the presence or absence of DMSO. Synaptosomes which
underwent the freeze/thaw cycle in the presence of
DMSO exhibited marked Ca21-dependent, K1-evoked
[3H]glutamate release during 20- and 40-s incubation at
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308C. In the absence of Ca21, K1-evoked [3H]glutamate
release was not observed at either incubation time. Little or
no release of [3H]glutamate was observed under non-
depolarizing conditions, whether or not Ca21 was present.
These results were essentially the same observed with
DMSO-untreated, unfrozen (`intact') synaptosomes (data
not shown). In contrast, when synaptosomes were subjected
to freeze/thaw treatment without DMSO, no K1-evoked,
Fig. 3 Effect of IPF incorporated into synaptosomes on exocytotic
glutamate release at various times. Incorporation into synaptosomes
of Mono Q-puri®ed IPFa was allowed at a concentration of 126 nM,
as described in Materials and methods. In control experiments, an
identical volume of an IPF-free solution containing 300 mM NaCl,
1 mM EDTA, 0.2 mM phenylmethyl sulfonyl ¯uoride (PMSF), and
20 mM Tris±HCl, pH 7.6 (vehicle solution) was used. Glutamate
release was allowed to proceed at 308C for the various times indi-
cated. Values at 0-s incubation have been subtracted from all data;
the values subtracted were 5006 d.p.m. (± IPF; X) and 3738 d.p.m.
(1 IPF; W) for (a), and 4639 d.p.m. (± IPF; X) and 5230 d.p.m.
(1 IPF; W) for (b). The amount of [3H] glutamate released during
60 s in the absence and presence of IPF represented
0.21 1 0.007% and 0.07 1 0.004% for (a), and 0.21 1 0.019% and
0.06 1 0.009% for (b), respectively, of the total amount of [3H]
glutamate added to load synaptosomes. The data represent the
mean ^SEM of 3 independent experiments, using 3 separate
synaptosome preparations.
Fig. 4 Glutamate release and intrasynaptosomal content of IPF as
a function of added amount of IPF. (a,b) Glutamate release.
Synaptosomes were permeabilized and resealed in the presence of
various amounts of isolated IPF (0, 42, 84, and 126 nM for IPFa [a]
or IPFbg [b]) and subjected to [3H]glutamate release for 40 s at
308C, as described in Materials and methods. The value at 0-s
incubation has been subtracted from all data. The values subtracted
ranged from 4378 (IPFa, 126 nM) to 5485 (vehicle for 42 nM IPFa)
d.p.m. for (a), and 4327 (IPFbg, 84 nm) to 5485 (vehicle for 42 nM
IPFbg) d.p.m. for (b). The amounts of [3H] glutamate released in the
presence of Ca21 and 52.7 mM KCl represented 0.16±0.17% for the
vehicles in (a) and 0.16±0.18% for the vehicles in (b), respectively,
of the total amount of [3H] glutamate added to load synaptosomes.
The data represent the mean ^SEM of 3 independent experiments,
using 3 separate synaptosome preparations. Student's two-tailed
t-test p-values (vs. vehicle): *p  0.027; **p  0.004;
***p  0.0006; 1p  0.0002; 11p , 0.0001; 111p , 0.0001. (c)
IPF content. Synaptosomes were subjected to permeabilization and
resealing in the presence of puri®ed IPF, 42 (lane 1), 84 (lane 2),
and 126 (lane 3) nM or in its absence (lane 4), followed by washing
as described in Materials and methods. Washed synaptosomes
were incubated for 10 min at 308C and lysed; intrasynaptosomal IPF
was monitored by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE)/ECL, using IPF N-terminal decapeptide
antibodies as the probe, as described in Materials and methods.
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Ca21-dependent release of [3H]glutamate was observed.
These results indicate that the synaptosome can retain its
primary functional property, namely, the ability to release a
neurotransmitter (glutamate, in this case) in response to
depolarization in the presence of Ca21, even when it is
subjected to freeze/thaw treatment, so long as DMSO (e.g.
5%) is present during the freeze/thaw cycle. These
observations are in agreement with those previously
reported by Nichols et al. (1989), indicating that synapto-
somes are permeabilized and resealed by freeze/thaw
treatment in the presence of DMSO.
Time course of glutamate release from permeabilized/
resealed synaptosomes
Fig. 2 shows that K1-evoked, Ca21-dependent [3H]gluta-
mate release from the permeabilized and resealed synapto-
some is dependent on incubation time. The Ca21-dependent,
evoked release appears to begin to slow down at around 20 s
under these conditions. In the absence of Ca21, K1-induced
depolarization elicited little if any release at any of the
incubation times tested (Fig. 2a). In the absence of
depolarization, Ca21 caused little if any release of
[3H]glutamate (Fig. 2b).
IPF inhibits [3H] glutamate release from synaptosomes
To investigate the effect of IPF on depolarization-induced
Ca21-dependent release of glutamate, IPF was introduced
into synaptosomes as described in Materials and methods.
The amount of [3H]glutamate released from IPFa-treated
synaptosomes was about 65% smaller than that from control
synaptosomes, at all incubation times tested (Fig. 3a). Since
IPFbg, a mixture of IPFb and IPFg presumably produced
during IPF puri®cation, also inhibited [3H] glutamate uptake
into isolated synaptic vesicles with almost identical potency
(OÈ zkan et al. 1997; also in this study), we have examined
the effect of introduction of IPFbg into synaptosomes on
glutamate release. As shown in Fig. 3(b), IPFbg reduced
[3H]glutamate release from synaptosomes throughout the
incubation period. The IPFbg-induced inhibition of
[3H]glutamate release at 20, 30, 40 and 60 s incubation
was 73, 81, 75 and 72%, respectively.
Concentration-dependence of inhibition by IPF
Fig. 4(a) shows the effect of increasing the concentration of
IPFa on [3H]glutamate release. IPFa reduced Ca21-
dependent, K1-evoked [3H]glutamate release from synapto-
somes in a dose-dependent manner. The IPFa-induced
inhibition of [3H]glutamate release at 42, 84, and 126 nm
was 26, 43 and 61%, respectively. These are calculated
concentrations in the medium during the freeze/thaw and do
not necessarily represent actual IPFa concentrations in the
permeabilized and resealed synaptosomes; the latter may be
lower than the former. This preparation of IPF(a or bg)
caused 50% inhibition of vesicular glutamate uptake into
Fig. 5 Glutamate release and intrasynaptosomal content of a-fodrin
as a function of added amount of fodrin. (a) Glutamate release.
Synaptosomes were permeabilized and resealed in the presence of
various amounts of isolated fodrin (0, 17, 51 and 85 nM) or of IPFbg
(0 and 126 nM as positive control), and subjected to [3H]glutamate
release for 40 s at 308C, as described in Materials and methods.
Fodrin was puri®ed in a solution consisting of 10 mM NaH2PO4,
0.2 mM NaEDTA, 1 mM NaN3 and 0.4 mM dithiothreitol, pH 7.5. The
vehicle is the medium described above, used for the isolation of
fodrin. The value at 0 s has been subtracted from all data. The
values subtracted ranged from 2876 (control) to 3961 (fodrin, 17 nM)
dpm. The amounts of [3H] glutamate released in the presence of
Ca21 and 52.7 mM KCl for the IPFbg and fodrin vehicles repre-
sented 0.14 1 0.016% and 0.12 1 0.016%, respectively, of the total
amount of [3H] glutamate added to load synaptosomes. The data
represent the mean ^SEM of 3 independent experiments, using 3
separate synaptosome preparations. (b) Fodrin content. Synapto-
somes were subjected to permeabilization and resealing in the
absence (lane 1) or presence of puri®ed fodrin, 17 nM (lane 2),
51 nM (lane 3), and 85 nM (lane 4), as described in Materials and
methods, followed by the treatment described in the Fig. 4 legend.
a-Fodrin and immunoreactive processed a-fodrin were detected by
SDS-PAGE/ECL, using the a-fodrin N-terminal decapeptide
antibodies as the probe.
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isolated synaptic vesicles at 42 nm (data not shown). This is
comparable to the IPF potency on release; the apparent,
though small, discrepancy could be due to potential
incomplete equilibration of IPF concentration between the
outside and inside of the synaptosome during the freeze/
thaw period. IPF did not affect [3H]glutamate release in the
absence of Ca21 under depolarizing conditions or basal
release. Similar dose-dependent inhibition of [3H]glutamate
release was also observed with IPFbg (Fig. 4b). In order to
con®rm that IPF was indeed introduced into synaptosomes
by freeze/thaw treatment, the synaptosomal cytosol fraction
was assayed for IPF by Western blot with anti-IPF
N-terminal peptide antiserum. As shown in Fig. 4(c), the
intrasynaptosomal content of IPF was increased as a
function of the amount of IPF present in the medium during
the freeze/thaw period. In the absence of added IPF, IPF was
hardly detected. This could be due to its leakage into the
larger volume of the medium, as a result of the freeze/thaw-
induced permeabilization and resealing. These results
support the notion that an increase in IPF within the
synaptosome leads to a decrease in the amount of [3H]
glutamate released by the exocytotic mechanism.
Fodrin introduction into synaptosomes does not alter
[3H]glutamate release
Sequence analysis of IPF suggests that IPF is produced by at
least two steps of proteolytic cleavage, from the a subunit of
fodrin, a major cytoskeletal protein (OÈ zkan et al. 1997). IPF
thus formed has the N-terminal sequence distinct from that
of a-fodrin; the C-terminal sequence of IPF is yet to be
determined. In contrast to IPF, neither isolated fodrin nor a-
fodrin exhibited inhibitory activity in glutamate uptake into
isolated synaptic vesicles (data not shown). Here, isolated
fodrin was incorporated into synaptosomes by the same
procedure used for introduction of IPF into synaptosomes.
Its effect on [3H]glutamate release from these synaptosomes
was then compared with the effect of incorporation of IPF
determined in parallel experiments. As shown in Fig. 5(a),
introduction of isolated fodrin had no effect on [3H]gluta-
mate release even at the highest concentration tested
(85 nm), in contrast to IPFa, which exhibited substantial
inhibition at this concentration (see Fig. 4a). At 126 nm,
IPFa and IPFb caused similar degrees of inhibition in the
experiments shown in Figs 4(a) and 5(a). Moreover,
introduction of isolated a-fodrin (at 293 nm, calculated
based upon the molecular weight of 284 000) into synapto-
somes led to no inhibition of glutamate release (data not
shown). Fig. 5(b) indicates that fodrin is incorporated into
synaptosomes in a concentration-dependent manner.
Fodrin's inability to affect [3H] glutamate release is
therefore not due to its failure to enter the synaptosome.
The two prominent bands above the a-fodrin band probably
represent aggregated forms of a-fodrin.
Fig. 6 Effects of extrasynaptosomal IPF on [3H]glutamate release
from permeabilized/resealed synaptosomes and on intrasynapto-
somal IPF content. (a) Glutamate release. Synaptosomes were ®rst
subjected to permeabilization (without IPF), resealing, washing,
incubation at 308C for 10 min, and two ®nal washings, and sus-
pended in BSS, as described in Materials and methods. IPFa was
then added to give a ®nal concentration of 126 nM (after resealing).
Aliquots (250 mL) were assayed for [3H]glutamate release as
described in Materials and methods. In parallel positive control
experiments, synaptosomes were permeabilized and resealed in the
presence of IPFa 126 nM, further processed, and aliquots (250 mL)
analyzed for [3H]glutamate release, in the same manner described
in the Fig. 4 legend. The value at 0 s has been subtracted from all
data. The values subtracted were 3264 d.p.m. (vehicle) and 3549
d.p.m. (IPFa, 126 nM), for `during permeabilization', and 3456 d.p.m.
(vehicle) and 3396 d.p.m. (IPFa, 126 nM) for `after permeabilization'.
The amount of [3H] glutamate released in the presence of Ca21 and
52.4 mM KCl for both vehicles represented 0.15% of the total
amount of [3H] glutamate added to load synaptosomes. The data
represent the mean ^SEM of 3 independent experiments, using 3
separate synaptosome preparations. (b) Intrasynaptosomal content
of IPF. IPFa was added to the resealed synaptosomes just prior to
the [3H] glutamate release period, to give ®nal concentrations of 0
(lane 1), 42 nM (lane 2), 84 nM (lane 3), and 126 nM (lane 4), as
described above. Synaptosomes were lysed; the lysate was
concentrated and analyzed for IPF, as described in the Fig. 4
legend.
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Extrasynaptosomal IPF has no effect on [3H] glutamate
release
In order to con®rm that IPF affects glutamate release
intrasynaptosomally as opposed to extrasynaptosomally,
synaptosomes were ®rst permeabilized, resealed, washed
and then subjected to glutamate release in the presence or
absence of IPF (126 nm) under the four conditions described
in the Fig. 4 legend. Under these conditions, IPF had no
effect on glutamate release from synaptosomes (Fig. 6a).
Fig. 6(b) shows that IPF was hardly entrapped into
synaptosomes when added after synaptosomes had been
resealed. These results indicate that IPF does not act from
the exterior of the synaptosome but rather functions within
the synaptosome.
Neurotransmitter speci®city of IPF action
IPF has been shown to inhibit not only accumulation of
glutamate into isolated synaptic vesicles but also accumu-
lation of GABA (OÈ zkan et al. 1997), suggesting that IPF
may not speci®cally regulate glutamate storage in vivo. In
order to gain insight into this matter, we have determined
the effect of IPF incorporation into synaptosomes on the
subsequent exocytotic release of GABA and serotonin (a
representative monoamine neurotransmitter). As shown in
Fig. 7, IPFa also reduced depolarization-induced, Ca21-
dependent release of GABA and serotonin, although the
magnitude of these effects was somewhat smaller than the
effect on glutamate release. IPFa-induced inhibition of
exocytotic release of [3H]glutamate, [3H]GABA, and
[3H]serotonin was 71, 58 and 54%, respectively. These
Fig. 7 Neurotransmitter speci®city of IPF. The assay conditions for
GABA and serotonin release were the same described for the glu-
tamate release assay, except that [3H]glutamate was replaced by
7.5 mCi of [3H]GABA or 5-hydroxy[3H]tryptamine, creatine sulfate,
and 50 mM glutamate by 50 mM GABA or 50 mM 5-hydroxytrypta-
mine, creatine sulfate. Synaptosomes were permeabilized and
resealed in the absence or presence of IPFa 126 nM and then sub-
jected to the release assay as described in the Fig. 4 legend. The
value at 0 s has been subtracted from all data. The values sub-
tracted were 3504 d.p.m. (vehicle) and 3500 d.p.m. (IPFa) for
glutamate; 930 d.p.m. (vehicle) and 920 d.p.m. (IPFa) for GABA;
and 1743 d.p.m. (vehicle) and 1851 d.p.m. (IPFa) for serotonin.
The amounts of [3H] glutamate released in the presence of Ca21
and 52.7 nM KCl, in the absence of IPFa, for the glutamate, GABA,
and serotonin represented 0.11 1 0.008%, 0.022 1 0.0004%, and
0.083 1 0.007%, respectively, of the total amount of [3H]
glutamate, GABA, and serotonin added to load synaptosomes. The
data represent the mean ^SEM of 3 independent experiments,
using 3 separate synaptosome preparations. *Two-tailed p-values:
*p  0.0024; **p  0.016.
Fig. 8 IPF immunoblot of rat brain subcellular fractions. Each sub-
cellular fraction (100 mg of protein) was subjected to SDS poly-
acrylamide gel (6%) electrophoresis, transferred to a nitrocellulose
membrane, and immunoblotted with an antiserum raised against IPF
N-terminal decapeptide. Lane 1, homogenate (H); Lane 2, nuclear
and cell debris pellet (P1); Lane 3, synaptosomal and mitochondrial
pellet (P2); Lane 4, microsomal pellet (P3); Lane 5, perikaryon cyto-
sol supernatant (S1); Lane 6, synaptosomal cytosol (S2); Lanes 7
and 9, crude synaptic vesicles (SV); Lane 8, plasma membrane/
mitochondria/myelin fraction (P4); Lane 10, crude synaptic vesicle
subfraction A (0.32 M sucrose); Lane 11, crude synaptic vesicle sub-
fraction B (0.40 M sucrose); Lane 12, crude synaptic vesicle
subfraction C (0.60 M sucrose).
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results raise the possibility that IPF could affect vesicular
storage of multiple neurotransmitters in vivo.
Subcellular distribution of IPF
In order for IPF to play a physiological role as a vesicular
neurotransmitter storage inhibitor, IPF would have to occur
in the nerve ending. To address this issue, a freshly prepared
rat brain homogenate was subfractionated and each
subcellular fraction analyzed for IPF. Fig. 8 shows that
IPF (Mr  138 000) is present in the rapidly prepared
homogenate, indicating that it occurs in the intact cell; this
rules out the possibility that IPF is a puri®cation artifact. Of
interest, the Figure also shows that IPF, of all the subcellular
fractions tested, is most concentrated in the synaptosomal
cytosol fraction. It was hardly detected in the nuclear
fraction and the plasma membrane/mitochondrian/myelin
fraction derived from the P2 fraction. However, signi®cant
amounts of IPF were found in the puri®ed synaptic vesicle
fraction (Fig. 8, lane 11); this is consistent with high af®nity
of IPF for synaptic vesicles, as judged by its high potency in
vesicular glutamate/GABA uptake inhibition (OÈ zkan et al.
1997).
Discussion
Neural communication is thought to be most effectively
modulated at the level of synaptic transmission. A variety
of evidence indicates that there are diverse modes of
presynaptic as well as postsynaptic modulation. Presynaptic
regulation results in an alteration in the amount of
neurotransmitter released from the nerve terminal per
given period of time. This regulation can be achieved by
modulating (a) voltage-dependent calcium channels
(Dolphin 1990; Miller 1990; Baskys and Malenka 1991;
Barrie and Nicholls 1993; Colmers and Bleakman 1994;
Dittman and Regehr 1996; Stefani et al. 1996; Takahashi
et al. 1996); (b) potassium channels (Kandel and Schwartz
1992; Augustine 1990; Herrero et al. 1992; Robitaille and
Charlton 1992); (c) the Na1/Ca21 exchanger (Gleason et al.
1994; Bouron and Reuter 1996); (d) the nicotinic acetylcho-
line receptor non-selective cation channel (McGehee et al.
1995); (e) the cyclic nucleotide-gated channel (Rieke and
Schwartz 1994; Savchenko et al. 1997); (f) transition from
the neurotransmitter pool reserve state to the ready-release
state, or priming process (Bittner and Holz 1992; Greengard
et al. 1993; Neher and Zucker 1993; Smith et al. 1998); and
(g) the ®nal exocytotic release process (Prince and Stevens
1992; Scholz and Miller 1992; Silinsky and Solsona 1992;
Chavez-Noriega and Stevens 1994; Capogna et al. 1996;
Dittman and Regehr 1996; Trudeau et al. 1996; Kinney et al.
1998), not to mention neurotransmitter synthesis. In
addition, it is conceivable that the amount of neurotrans-
mitter to be released could be altered by varying the synaptic
vesicleõÂs transmitter storage activity or capacity. Relatively
little attention had been paid to this aspect of the
endogenous regulation of neurotransmission.
Observations presented in this communication provide
evidence that endogenous substances in the nerve terminal,
such as IPF, might play a role in regulating neurotransmitter
release by inhibiting neurotransmitter accumulation into
synaptic vesicles. We have previously provided evidence
that isolated IPF potently inhibits glutamate uptake into
isolated synaptic vesicles; IPF is devoid of inhibitory
activity toward ATP-independent glutamate uptake as well
as toward Na1-dependent glutamate uptake (OÈ zkan et al.
1997). In the present study, we have loaded synaptic vesicles
within the synaptosomes with [3H] glutamate, using
conditions optimal for glutamate uptake into isolated
synaptic vesicles (i.e. in the presence of Mg-ATP and a
low millimolar chloride) in the absence or presence of IPF,
and measured the subsequent [3H] glutamate release. We
have shown that IPF leads to a concentration-dependent
reduction of exocytotic release of glutamate over time
when introduced, together with [3H] glutamate, into
synaptosomes.
The potency of IPF in release (IC50  ,84 nm) was
found to be in general agreement with that in glutamate
uptake into isolated synaptic vesicles (IC50  26 nm). This
would argue for the notion that the IPF-induced decrease in
the amount of exocytotically released glutamate is mediated
by inhibition by IPF of vesicular glutamate uptake. IPF does
not bear the actin-binding domain of fodrin; IPF is within
the N-terminal half of a-fodrin (OÈ zkan et al. 1997) and actin
binds to the N-terminal region of b-fodrin (Karinch et al.
1990). This rules out the possibility that the inhibitory effect
of IPF on release is mediated by an alteration in the
interaction with actin. The role of actin in mediating IPF-
induced inhibition is also ruled out since incorporation into
synaptosomes of puri®ed fodrin, which is capable of inter-
acting with actin (Goodman et al. 1995), failed to affect [3H]
glutamate release. However, alternative possibilities, such as
the effect on other vesicle priming steps and the ®nal release
step, in addition to or instead of vesicular storage of
transmitters, are not ruled out at present. It also remains to
be determined whether synaptic vesicle glutamate content is
reduced within the IPF-containing synaptosomes.
Since discovery of the miniature endplate potential at the
neuromuscular junction and formulation of the quantal
release theory (Fatt and Katz 1952; Del Castillo and Katz
1954), much study had focused on alteration of quantal
content (quantal number) and its mechanism. We postulate
that IPF might function as an endogenous regulator of this
quantal release. Recent evidence points to the notion that
quantal size is variable and that vesicular neurotransmitter
content can be altered (Doherty et al. 1984; Whitton et al.
1986; Bekkers et al. 1990; Van der Kloot 1991; Stevens
1993). At the neuromuscular synapse, quantal size can be
changed under certain conditions, such as prolonged
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stimulation, an increase in intracellular Ca21, exposure to
acetylcholine agonists and hypertonic solutions, as well as
exposure to vesamicol, a potent inhibitor of the vesicular
acetylcholine transporter. More recently, Brailoiu and Van
der Kloot (1996) have shown that acetylcholine quantal size
is reduced by introduction of acetylcholine esterase or the
choline acetyltransferase inhibitor bromoacetylcholine into
motor nerve endings. In the central nervous system,
Pothos et al. (1998) have provided direct evidence that the
number of dopamine molecules per releasable quantum
from mid-brain dopaminergic neurons is increased by
exposure either to a glial-derived neurotrophic factor
(GDNF) or to the dopamine precursor l-dihydroxyphenyla-
lanine (l-DOPA).
IPF may represent the ®rst example of an endogenous
substance which can intracellularly control quantal size of
amino acid neurotransmitters, not by regulating their
synthesis, but by modulating their uptake into synaptic
vesicles. Controlling quantal size may be important in
preventing neurotransmitter over¯ow onto neighboring
synapses and/or abnormally prolonged activation of post-
synaptic receptors, as well as in modulating build-up of the
threshold potential required for triggering the action
potential.
Evidence presented here indicates that, under in vitro
conditions, IPF introduced into the synaptosome is capable
of decreasing the amount of exocytotically released
glutamate, GABA and serotonin. This suggests that IPF
can inhibit uptake of monoamine transmitters, as well as of
glutamate and GABA, into synaptic vesicles within
synaptosomes. This is somewhat at odds with previous
work which demonstrated that IPF has little effect on
catecholamine uptake into dense-core granules isolated from
chromaf®n cells (OÈ zkan et al. 1997). Amino acid neuro-
transmitters are stored in clear, small synaptic vesicles,
whereas monoamine transmitters, including serotonin, are
stored in both clear vesicles and dense-core vesicles (Maley
et al. 1990; Bruns and Jahn 1995; Johnson and Yee 1995).
These observations, taken together, raise the possibility that
several, if not all, types of clear vesicles may share a
common IPF binding site or protein, de®cient in dense-core
vesicles. Consistent with the proposed role of IPF as a
presynaptic regulator of exocytotic glutamate release,
speci®c content of IPF was found to be highest in the
synaptic vesicle fraction of all brain subcellular fractions
tested (Fig. 8). Whether IPF regulation occurs with
multiple types of neurotransmitters in vivo is not known.
It would depend upon whether IPF is present, for example,
in the glutamatergic, GABAergic, or monoaminergic nerve
terminal.
IPF is structurally related to, but functionally distinct
from, the a subunit of the major cytoskeletal protein
fodrin. In contrast to IPF, neither isolated fodrin nor its a
subunit affects vesicular glutamate uptake or glutamate
release. IPF differs from a-fodrin in its N-terminal
sequence and presumably in its C-terminal sequence as
well (OÈ zkan et al. 1997). Based upon amino acid
sequence analysis, it is thought that IPF is produced from
a-fodrin via two or more steps of cleavage. However, how
IPF is produced and its activity regulated remain to be
elucidated.
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